TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02794571
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m\^2 oral dose will be administered twice daily (BID) on Days 1 through 14 of each 21-day cycle. On Day 1 of Cycle 1, the first dose of capecitabine will be administered prior to the atezolizumab and tiragolumab infusion.
Study: NCT01347060
Drug: inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
Study: NCT02945033
Drug: placebo intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
Study: NCT04570384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.
Study: NCT03518021
Drug: placebo, intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same spray but without naloxone. Nasal spray will be administered with one puff (100 microL +/- 10%) in one nostril using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued.
Study: NCT03518021
Drug: placebo, intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Sodium Chloride Injection 9mg/ml, will be administered as a 2 ml intramuscular injection in the deltoid muscle
Study: NCT01278485
Drug: Sulphonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU administered according to usual practice.
Study: NCT01278485
Drug: Metformn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin administered according to usual practice.
Study: NCT02886299
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03531736
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4)
Study: NCT01394679
Drug: (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
Study: NCT01888861
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients in this arm were received 900mg placebo through NG tube.
Study: NCT03779438
Drug: 17-OHPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
Study: NCT01394679
Drug: 18 F FDG followed by PET/CT imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 18 F FDG range of 10-20 mCi
Study: NCT00873275
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin, 5-FU and Oxaliplatin
Study: NCT00873275
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment
Study: NCT00873275
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
Study: NCT03198871
Drug: Acetaminophen Injectable Product
Normalized name: acetaminophen Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively
Study: NCT01031888
Drug: Conventional postoperative eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical steroid, antibiotic and mydriatics
Study: NCT01826487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as per the schedule specified in the arm.
Study: NCT00984503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
Study: NCT00984503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
Study: NCT01254448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
Study: NCT01387347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
Study: NCT01428466
Drug: GSK2585823
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLDM1%/BPO3%
Study: NCT02559648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated.
Study: NCT01657370
Drug: MK-1602
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration.
Study: NCT01657370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration.
Study: NCT01657370
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded.
Study: NCT04319757
Drug: ACE1702
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously
Study: NCT04319757
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lympho-conditioning agent
Study: NCT03875638
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a capsule that is identical in appearance to the levetiracetam
Study: NCT01068184
Drug: AZD6553
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple oral dose
Study: NCT01068184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single or multiple oral dose
Study: NCT03893526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo day
Study: NCT04209556
Drug: PF-06826647 100 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product
Study: NCT04209556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo
Study: NCT04209556
Drug: PF-6826647 400 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product
Study: NCT01301677
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone liquid formulation
Study: NCT02153112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline solution
Study: NCT00272792
Drug: Sapropterin Dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
Study: NCT00272792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
Study: NCT00864149
Drug: Coreg® 12.5 mg Tablets , single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
Study: NCT04375436
Drug: NTRX-07-SDD
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTRX-07-SDD for oral administration
Study: NCT03680885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
Study: NCT02389244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression
Study: NCT04603001
Drug: LY3410738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral LY3410738
Study: NCT04633330
Drug: AHCC®capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.
Study: NCT04633330
Drug: Simulation of AHCC®capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.
Study: NCT04261777
Drug: Ferrotran® (Ferumoxtran-10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrotran® in a dose of 0.13 mL/kg body weight of the reconstituted freeze-dried preparation (i.e. 2.6 mgFe/kg body weight). The recommended dose should be diluted in 100 mL of NaCl 9 mg/mL (0.9%) solution for injection/infusion prior to administration via the infusion filter as a slow intravenous infusion over 30 minutes (at a maximum rate of 4 mL/min).~Ferrotran® will be administered once to each patient. Histologically confirmed diagnosis and pre-operative staging are performed prior to the study as part of standard care. Surgery (RP with ePLND) and sampling of tissue specimens is performed after the Ferrotran®-enhanced MRI as part of standard care.
Study: NCT00525421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01098747
Drug: Novel Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
Study: NCT01098747
Drug: Standard Ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of standard ibuprofen (400mg)
Study: NCT01098747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of placebo
Study: NCT02823002
Drug: Buffer
Normalized name: Buffers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Bicarbonate
Study: NCT03766984
Drug: Diclofenac sodium 25 mg
Normalized name: diclofenac sodium 25 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
Study: NCT03766984
Drug: Diclofenac sodium 25 mg/Tramadol hydrochloride 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet containing diclofenac sodium 25 mg and tramadol hydrochloride 25 mg (Laboratorios Tecnandina S.A., Ecuador)
Study: NCT00216333
Drug: combined fixed dose combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02829151
Drug: Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty
Study: NCT00276419
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks
Study: NCT00276419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
Study: NCT00144326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03186638
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02563795
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To compare low dose spinal anesthesia with bupivacaine+ fentanyl alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
Study: NCT00945009
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04304560
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar Placebo oral tablet
Study: NCT02482311
Drug: AZD 1775
Normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food.
Study: NCT01697709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules
Study: NCT00022178
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02829151
Drug: Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
Study: NCT00022178
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00022178
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03793621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single rising oral dose
Study: NCT00602693
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg intravenous over 2 hours on Day -6
Study: NCT02360592
Drug: Interleukin 2
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: In arm 3, Interleukin 2 is used for 12 weeks
Study: NCT03394482
Drug: Lu AF35700 5 mg clinical formulation
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AF35700 tablets 5 mg oral single dose
Study: NCT03394482
Drug: Lu AF35700 10 mg clinical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AF35700 tablets 10 mg oral single dose
Study: NCT03394482
Drug: Lu AF35700 20 mg clinical formulation
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AF35700 tablets 20 mg oral single dose
Study: NCT04817202
Drug: hzVSF-v13 (intravenous, single dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)
Study: NCT04817202
Drug: hzVSF-v13 (subcutaneous, single dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: 100mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
Study: NCT04817202
Drug: hzVSF-v13 (intravenous, multiple dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: 100mg / 400mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
Study: NCT04817202
Drug: Placebo (intravenous, single dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1 (single administration)
Study: NCT04817202
Drug: Placebo (subcutaneous, single dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: 0.9% NaCl Solution Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
Study: NCT04817202
Drug: Placebo (intravenous, multiple dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
Study: NCT04093232
Drug: Hymovis
Normalized name: Hymovis
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive 2 ultrasound guided Hymovis injections and the goal of the study is to correlate responsiveness to subjects unique SF biomarker panel results before the first Hymovis injection and identify potential mechanism of action of those OA patients who receive the greatest benefit.
Study: NCT04047446
Drug: Exparel 133 MG Per 10 ML Injection
Normalized name: Exparel 133 MG per 10 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)
Study: NCT00565565
Drug: BAY60-4552
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
Study: NCT01049373
Drug: HDC
Normalized name: ALCOHOL 375 mL in 500 mL TOPICAL GEL [PhDClean Hand Sanitizer Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.
Study: NCT01049373
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 drops, t.i.d, 15 weeks
Study: NCT02455869
Drug: SRP and Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Study: NCT03564886
Drug: Hyperosmolar Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
Study: NCT03564886
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate Ringer's (LR, 273mOsm/L)
Study: NCT00230464
Drug: LAF 237
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01720394
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
Study: NCT00812955
Drug: ABT-143
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 8 weeks
Study: NCT00812955
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily for 8 weeks simvastatin capsules 40 mg
Study: NCT03200002
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
Study: NCT00329030
Drug: Autologous transplantation using rituxan/BEAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
Study: NCT00329030
Drug: Autologous transplantation using Bexxar/BEAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
Study: NCT03483389
Drug: Alcohol, Ethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized within-subjects design
Study: NCT04792385
Drug: E4/DRSP 15/3 mg combined tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.
Study: NCT03978039
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as per standard of care